TITLE

Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?

AUTHOR(S)
Laine, Loren; Hennekens, Charles
PUB. DATE
January 2010
SOURCE
American Journal of Gastroenterology;Jan2010, Vol. 105 Issue 1, p34
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Current consensus recommendations state that patients prescribed clopidogrel plus aspirin should receive a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding. Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes. Clopidogrel users with decreased CYP2C19 function have less inhibition of platelet aggregation and increased cardiovascular (CV) events. As PPI metabolism also involves CYP2C19, it was hypothesized that competition by PPIs might interfere with clopidogrel's action. Omeprazole, but not other PPIs, worsens surrogate markers of clopidogrel efficacy. Some (but not all) observational studies show that clopidogrel users prescribed PPIs have increased risks of CV events (hazard/odds ratios=1.25–1.5). When effect sizes are small to moderate (relative risks<1.5–2.0), however, it is only possible to conclude whether statistical associations are valid in randomized trials. A randomized trial of omeprazole vs. placebo in clopidogrel users showed no difference in CV events (hazard ratio=1.02,0.70–1.51). Thus, current evidence does not justify a conclusion that PPIs are associated with CV events among clopidogrel users, let alone a judgment of causality. Nonetheless, positive results from some observational studies and biological plausibility have led some health-care providers to accept that PPIs reduce clopidogrel's efficacy. The US Food and Drug Administration (FDA) recommends that “concomitant use of drugs that inhibit CYP2C19 (e.g., omeprazole) should be discouraged.” As the presence of PPIs and clopidogrel in plasma is short lived, separation by 12–20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential, though unproven, clinical interaction. PPI may be given before breakfast and clopidogrel at bedtime, or PPI may be taken before dinner and clopidogrel at lunchtime.
ACCESSION #
47342809

 

Related Articles

  • Omeprazole's effect on clopidogrel. Elliott, William T. // Clinical Oncology Alert;Jan2010 Supplement 2, p2 

    The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) on avoiding the combination of clopidogrel with omeprazole to prevent reducing the effectiveness of clopidogrel by about half. The warning is based on the results of studies published in 2009 which suggested...

  • PPIs reduce clopidogrel-induced GI bleeding without reducing efficacy.  // Reactions Weekly;5/15/2010, Issue 1301, p2 

    This article reports on a study on the use of proton pump inhibitors (PPIs) in combination with clopidogrel to reduce the risk of serious gastrointestinal (GI) bleeding.

  • Omeprazole's effect on clopidogrel. Elliott, William T. // Infectious Disease Alert;Jan2010 Supplement2, p2 

    The article reports on a warning issued by the U.S. Food & Drug Administration (FDA) on the clinical use of combined clopidogrel and omeprazole. Omeprazole and clopidogrel are commonly prescribed to prevent gastrointestinal bleeding. However, studies have shown that omeprazole reduces the...

  • Omeprazole's effect on clopidogrel.  // Clinical Cardiology Alert;Jan2010 Supplement 2, p2 

    The article reports on a warning issued by the U.S. Food & Drug Administration (FDA) on the clinical use of combined clopidogrel and omeprazole. Omeprazole and clopidogrel are commonly prescribed to prevent gastrointestinal (GI) bleeding. However, studies have shown that omeprazole reduces the...

  • Inter-Individual Variation in Pharmacokinetics of Proton Pump Inhibitors in Healthy Indian Males. Rani, Shubha; Padh, Harish // Indian Journal of Pharmaceutical Sciences;2006, Vol. 68 Issue 6, p754 

    Proton pump inhibitors have revolutionized the management of acid-peptic disorders in recent years. They have a broadly similar mechanism of action and are extensively metabolized in the liver via cytochrome P450 2C19 and 3A4 enzymes. A wide inter-individual variability in pharmacokinetics due...

  • Interaction between clopidogrel and proton pump inhibitors: A clinical overview. Nagavi, Jinesh B.; Gurupadayya, B. M. // International Journal of Pharmacy;Jul2014, Vol. 4 Issue 3, p141 

    Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Over recent years there has been much debate about whether some or all proton pump inhibitors might reduce the effectiveness of...

  • New black-box warning for Clopidogrel. Coleman, Craig I. // Drug Topics;May2010, Vol. 154 Issue 5, p14 

    The article presents information on an announcement made by the U.S. Food & Drug Administration (FDA) on March 12, 2010, according to which antiplatelet agent clopidogrel will require a new black-box warning about its reduced effectiveness in patients who are poor metabolizers of the drug. It is...

  • Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3. BUTLER, Christopher F.; PEET, Caroline; MCLEAN, Kirsty J.; BAYNHAM, Michael T.; BLANKLEY, Richard T.; FISHER, Karl; RIGBY, Stephen E. J.; LEYS, David; VOICE, Michael W.; MUNRO, Andrew W. // Biochemical Journal;6/1/2014, Vol. 460 Issue 2, p247 

    Production of drug metabolites is one area where enzymatic conversion has significant advantages over synthetic chemistry. These high value products are complex to synthesize, but are increasingly important in drug safety testing. The vast majority of drugs are metabolized by cytochromes P450...

  • A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Juurlink, David N.; Gomes, Tara; Ko, Dennis T.; Szmitko, Paul E.; Austin, Peter C.; Tu, Jack V.; Henry, David A.; Kopp, Alex; Mamdani, Muhammad M. // CMAJ: Canadian Medical Association Journal;3/31/2009, Vol. 180 Issue 7, p713 

    Background: Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Methods: We conducted a population-based nested case-control study among patients aged 66 years or older who commenced...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics